Before we send out missions to red dwarf stars, we need to double check their ability to sustain life.
Red dwarf stars are the most abundant in the universe and at the top of the list when searching for habitable planets. Why we don’t live around one?
😀
Cellular senescence, a state of permanent growth arrest, has emerged as a hallmark and fundamental driver of organismal aging. It is regulated by both genetic and epigenetic factors. Despite a few previously reported aging-associated genes, the identity and roles of additional genes involved in the regulation of human cellular aging remain to be elucidated. Yet, there is a lack of systematic investigation on the intervention of these genes to treat aging and aging-related diseases.
How many aging-promoting genes are there in the human genome? What are the molecular mechanisms by which these genes regulate aging? Can gene therapy alleviate individual aging? Recently, researchers from the Chinese Academy of Sciences have shed new light on the regulation of aging.
Recently, researchers from the Institute of Zoology of the Chinese Academy of Sciences (CAS), Peking University, and Beijing Institute of Genomics of CAS have collaborated to identify new human senescence-promoting genes by using a genome-wide CRISPR/Cas9 screening system and provide a new therapeutic approach for treating aging and aging-related pathologies.
BOSTON (PRWEB) November 18, 2020
What does it mean for multiplying cells in the body to be immortal? The cell DNA is being replicated over and over again while being divided equally between new cells produced by cell divisions. All the new cell components produced by the DNA code are mixing with the old cell components and being divided between the new cells. So, every cell is a new cell. There is nothing really immortal about any of them. Right?
Not quite. Stem cells responsible for renewing other mature body cells are different. For a long time, tissue cell scientists had a somewhat nebulous idea that stem cells had a special longevity in organs and tissues – that they were immortal cells, lasting for as long as the human lifespan. However, no one had a molecular concept for this idea of stem cell immortality until John Cairns, a pioneer of DNA replication, started thinking about DNA mutations and cancer in the 1970’s.
Circa 2013 henrietta lacks unlimited cell division sequenced allowing for immortality.
The HeLa cell genome is riddled with errors, raising questions about its continued use.
Circa 2018
CRISPR will realize its potential in plastic and reconstructive surgery only if plastic surgeons gain familiarity with this disruptive technology and become active contributors and leaders in applying CRISPR to their respective areas of expertise.
Circa 2020
Self-propelling magnetic nanorobots capable of intrinsic-navigation in biological fluids with enhanced pharmacokinetics and deeper tissue penetration implicates promising strategy in targeted cancer therapy. Here, multi-component magnetic nanobot designed by chemically conjugating magnetic Fe3O4 nanoparticles (NPs), anti-epithelial cell adhesion molecule antibody (anti-EpCAM mAb) to multi-walled carbon nanotubes (CNT) loaded with an anticancer drug, doxorubicin hydrochloride (DOX) is reported. Autonomous propulsion of the nanobots and their external magnetic guidance is enabled by enriching Fe3O4 NPs with dual catalytic-magnetic functionality. The nanobots propel at high velocities even in complex biological fluids. In addition, the nanobots preferably release DOX in the intracellular lysosomal compartment of human colorectal carcinoma (HCT116) cells by the opening of Fe3O4 NP gate.
Circa 2017 using this can lead to near Ironman or foglet bodies with the ability to self heal the human body. It could be used on smartphones to heal people not needing a doctor in the future. This also would allow for the biological singularity to happen.
This device shoots new genetic code into cells to make them change their purpose. Researchers say the chip could someday be used to treat injuries in humans. But they’ve got a long, long way to go.
A once forgotten technology, RNA editing has been gaining traction as a treatment for genetic conditions given its key advantages over CRISPR gene editing.
Since CRISPR-Cas9 gene editing was first reported in 2012, its promise of making gene editing faster, cheaper, and easier than ever before led to an explosion in the number of publications referring to this gene editing technology.
An increasing number of research labs and companies are aiming to translate CRISPR gene editing into therapies for genetic diseases. However, further research has unveiled that there are more limitations to using CRISPR-Cas9 to cure diseases than initially expected. For example, the technology has been reported to introduce off-target changes to the DNA, raising concerns about its safety.
